Neurology
Latest News
Post-AAIC 2025 Perspective on Advances in Alzheimer Diagnosis and Treatment: Rebecca M. Edelmayer, PhD
WATCH TIME: 5 minutes | Captions are auto-generated and may contain errors. "It was an incredible meeting at the Alzheimer's Association International...
Overviewing Phase 1/2 PACIFIC Trial of Bexicaserin in Developmental Epileptic Encephalopathies: Ingrid Scheffer, AO, PhD, FRACP, FAHMS, FAA
WATCH TIME: 4 minutes "For the first time, we have a regulatory trial that includes the full spectrum of developmental and epileptic encephalopathies,...
Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets
Kohlschütter, A., Schulz, A., Bartsch, U. & Storch, S. Current and emerging treatment strategies for neuronal ceroid lipofuscinoses. CNS Drugs 33, 315...
ANA2025 marks important milestones for the ANA and NINDS | Nature Reviews Neurology
Subjects Neurology In September 2025, the American Neurological Association (ANA) celebrates its 150th annual meeting (ANA2025), as well as the 75th a...
Digital Lifestyle App Levidex Fails to Meet Primary End Point for Early MS in POWER@MS1 Trial
Newly published findings from the randomized controlled POWER@MS1 trial (NCT03968172) assessing Levidex showed that the cognitive behavioral therapy-b...
Clinical Insights on Dyskinesia and Tremor in Parkinson Disease
Video content above is prompted by the following: Parkinson disease management presents significant clinical challenges when distinguishing between dy...
Analyzing Eptinezumab’s Ability to Extend Interictal Periods and Reduce Migraine Burden
Migraine, a leading cause of global disability, represents a complex neurobiological disorder with a range of symptoms, including headache, sensory se...
Advice to Improve Uptake of Newer ASM Therapies in Dravet Syndrome
Early Genetic Testing as the Foundation The most critical step in improving uptake of newer Dravet syndrome therapies is encouraging clinicians to ove...
Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose
According to a new announcement, Eisai and Biogen have begun a rolling submission to the FDA for its subcutaneous autoinjector formulation (SC-AI) of...
Large-Scale Study Highlights Therapeutic Benefits of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
A recently published study of more than 44,000 patients with idiopathic intracranial hypertension (IIH) showed that glucagon-like peptide 1 receptor a...
Post-AAIC 2025 Perspective on Advances in Alzheimer Diagnosis and Treatment: Rebecca M. Edelmayer, PhD
Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets
ANA2025 marks important milestones for the ANA and NINDS | Nature Reviews Neurology
Digital Lifestyle App Levidex Fails to Meet Primary End Point for Early MS in POWER@MS1 Trial
Clinical Insights on Dyskinesia and Tremor in Parkinson Disease
Analyzing Eptinezumab’s Ability to Extend Interictal Periods and Reduce Migraine Burden
Advice to Improve Uptake of Newer ASM Therapies in Dravet Syndrome
Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose
Large-Scale Study Highlights Therapeutic Benefits of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago